Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Autoinjector Usability in Psoriasis
NCT03875508Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With an Observer Rating of Successful Participant Self-administration at Week 28, Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16 and 5 more. Started Jun 2019; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03875508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875508.